Gilead (GILD) announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis to Eswatini and Zambia.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Promising Future in HIV Treatment and Oncology Drives Buy Rating
- Gilead Sciences’ Strategic Advancements in HIV Treatment Bolster Buy Rating and Future Revenue Prospects
- Early notable gainers among liquid option names on November 13th
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls
- Scotiabank starts 10 large cap drugmakers with ‘out-of-consensus’ positive view